Trends & Analysis

Alnylam reports new data on study of givosiran in acute hepatic porphyria

24 August 2020

Alnylam Pharmaceuticals has new data from the open-label extension (OLE) period of the ENVISION Phase 3 study This shows the long-term therapeutic benefit of givosiran in patients with acute hepatic porphyria (AHP)—an orphan disease that can be life threatening. The results were presented by study investigator Eliane Sardh, MD, during a webinar hosted by Alnylam. […]

ViiV Healthcare to present new HIV data at International AIDS Conference

24 August 2020

Continuing to challenge the current HIV treatment paradigm, data presented will investigate new and innovative treatment options for people living with HIV. ViiV Healthcare will be presenting over 20 abstracts during next week at the 23rd International AIDS Conference (AIDS 2020: Virtual), being held 6-10 July. Because of the COVID-19 pandemic, the conference will be […]

« Previous

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free